OX40/TNFRSF4/CD134 hFc Chimera, Human
OX40/TNFRSF4/CD134 HFc Chimera, Human

Loaded OX40/TNFRSF4/CD134 hFc Chimera, Human, hFc Tag on ProA-Biosensor, can bind Human OX40 Ligand (Trimer), His Tag with an affinity constant of 0.16 nM as determined in BLI assay (Gator® Prime).

OX40/TNFRSF4/CD134 HFc Chimera, Human

Immobilized Human OX40 Ligand (Trimer), His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for OX40/TNFRSF4/CD134 hFc Chimera, Human, hFc Tag with the EC50 of 34.2ng/ml determined by ELISA.

OX40/TNFRSF4/CD134 HFc Chimera, Human

The purity of OX40/TNFRSF4/CD134 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

OX40/TNFRSF4/CD134 HFc Chimera, Human

OX40/TNFRSF4/CD134 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

OX40/TNFRSF4/CD134 hFc Chimera, Human

Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation.
Z05727
¥52,232.00

Ask us a question
Product Introduction
Species Human
Protein Construction
OX40/TNFRSF4/CD134 (Leu29-Ala216)_x000D_
Accession # P43489		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 46.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-78 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • OX40/TNFRSF4/CD134 HFc Chimera, Human
    • OX40/TNFRSF4/CD134 HFc Chimera, Human

    Loaded OX40/TNFRSF4/CD134 hFc Chimera, Human, hFc Tag on ProA-Biosensor, can bind Human OX40 Ligand (Trimer), His Tag with an affinity constant of 0.16 nM as determined in BLI assay (Gator® Prime).

  • OX40/TNFRSF4/CD134 HFc Chimera, Human
    • OX40/TNFRSF4/CD134 HFc Chimera, Human

    Immobilized Human OX40 Ligand (Trimer), His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for OX40/TNFRSF4/CD134 hFc Chimera, Human, hFc Tag with the EC50 of 34.2ng/ml determined by ELISA.

  • OX40/TNFRSF4/CD134 HFc Chimera, Human
    • OX40/TNFRSF4/CD134 HFc Chimera, Human

    The purity of OX40/TNFRSF4/CD134 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • OX40/TNFRSF4/CD134 HFc Chimera, Human
    • OX40/TNFRSF4/CD134 HFc Chimera, Human

    OX40/TNFRSF4/CD134 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), also known as CD134 and OX40 receptor. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation.
Synonyms CD134; OX40; OX40L receptor; TNFRSF4; ACT-135; Ly-70; OX40 homologue; TXGP1L; IMD16

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.